120
Participants
Start Date
June 7, 2022
Primary Completion Date
April 3, 2026
Study Completion Date
April 3, 2026
Tuvusertib
Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
Lartesertib
Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
Avelumab
Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
Seoul National University Bundang Hospital, Seongnam-si
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica, Madrid
Hospital Universitario Quironsalud Madrid - NEXT Oncology, Madrid
Carolina Urologic Research Center, Myrtle Beach
Augusta University - formerly Georgia Regents University, Augusta
University of Miami School of Medicine, Miami
The University of Kansas Medical Center Research Institute, Inc., Kansas City
Mary Crowley Cancer Research Centers, Dallas
University of Texas M. D. Anderson Cancer Center - Partner, Houston
NEXT Oncology, San Antonio
Providence Medical Foundation, Santa Rosa
Royal North Shore Hospital, St Leonards
Calvary Mater Newcastle - PARENT, Waratah
Hospital Clinic de Barcelona - Servicio de Oncologia, Barcelona
Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I, Madrid
Princess Margaret Cancer Centre, Toronto
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
Korea University Guro Hospital, Seoul
Hospital QuironSalud Barcelona - Next Oncology, Barcelona
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY